Huberman LabHow Women Can Improve Their Fertility & Hormone Health | Dr. Natalie Crawford
Andrew Huberman and Dr. Natalie Crawford on science-based fertility and hormone strategies: testing, lifestyle, and key myths.
In this episode of Huberman Lab, featuring Dr. Natalie Crawford and Andrew Huberman, How Women Can Improve Their Fertility & Hormone Health | Dr. Natalie Crawford explores science-based fertility and hormone strategies: testing, lifestyle, and key myths Fertility is framed as a broad health marker tied to metabolic health, chronic inflammation, and long-term risks like cardiovascular disease and earlier mortality, rather than only the ability to get pregnant.
At a glance
WHAT IT’S REALLY ABOUT
Science-based fertility and hormone strategies: testing, lifestyle, and key myths
- Fertility is framed as a broad health marker tied to metabolic health, chronic inflammation, and long-term risks like cardiovascular disease and earlier mortality, rather than only the ability to get pregnant.
- Crawford advocates proactive assessment—especially AMH testing and ovulation tracking—to guide earlier, more informed reproductive decisions instead of waiting for “failure” to meet infertility definitions.
- The episode clarifies what can and cannot be tested: egg quantity (ovarian reserve) is approximated by AMH, while egg quality is inferred mainly from age, metabolic health, and clinical context.
- Lifestyle “non-negotiables” (sleep, stress, strength/muscle, nutrition, and toxin reduction) are positioned as major levers for egg/sperm outcomes, with specific warnings about cannabis, nicotine, and certain anti-inflammatories around ovulation.
- The discussion covers fertility preservation and assisted reproduction (egg freezing, IVF, embryo banking), addressing common myths, ethical debates, and access/insurance barriers, while highlighting patient choice and autonomy.
IDEAS WORTH REMEMBERING
5 ideasUse fertility as an early warning signal for broader health issues.
Crawford links infertility with higher rates of metabolic syndrome, cancer, cardiovascular events, stroke, and earlier death—often because infertility can be an early sign of inflammation or insulin resistance rather than the direct cause.
Get an AMH test proactively if you might want children.
AMH estimates ovarian reserve (egg quantity), not egg quality; knowing whether reserve is normal/low can change timelines and choices (try sooner, freeze eggs/embryos, investigate causes). She notes out-of-pocket AMH testing can be inexpensive (~$79) via common labs.
Track ovulation—not just periods—to detect early hormone/ovulation disorders.
Regular bleeding can miss early problems like a short luteal phase (<11 days), which may signal thyroid/prolactin issues, PCOS, low reserve, or other causes; ovulation tracking provides more sensitive insight than calendar-based cycle tracking.
Egg freezing/IVF does not “use up” eggs faster or cause early menopause.
Stimulation recruits the cohort of follicles already “out of the vault” that month; IVF aims to rescue more of that cohort from atresia rather than tapping the long-term reserve.
Avoid NSAIDs around ovulation when trying to conceive.
NSAIDs (e.g., ibuprofen/naproxen) can prevent follicle rupture, causing the hormonal pattern of ovulation without egg release; she advises limiting NSAIDs to period days if needed for cramps.
WORDS WORTH SAVING
5 quotesFertility is a health marker.
— Dr. Natalie Crawford
If you have infertility, you have increased rates of metabolic syndrome, cancer, heart attack, stroke, and dying early.
— Dr. Natalie Crawford
Menopause at its purest is ovarian failure.
— Dr. Natalie Crawford
We’re withholding a seventy-nine dollar test.
— Dr. Natalie Crawford
If you’re trying to get pregnant, you can take [NSAIDs] only when you’re on your period… but we don’t want you taking them for the rest of the cycle because you can prevent ovulation.
— Dr. Natalie Crawford
QUESTIONS ANSWERED IN THIS EPISODE
5 questionsAMH helps estimate egg quantity, not quality—how should someone interpret a “low AMH but regular cycles” result without panicking or dismissing it?
Fertility is framed as a broad health marker tied to metabolic health, chronic inflammation, and long-term risks like cardiovascular disease and earlier mortality, rather than only the ability to get pregnant.
What specific ovulation-tracking methods (LH strips, basal temp, cervical mucus, wearables) does Crawford find most reliable for detecting luteal phase issues in real-world patients?
Crawford advocates proactive assessment—especially AMH testing and ovulation tracking—to guide earlier, more informed reproductive decisions instead of waiting for “failure” to meet infertility definitions.
Crawford recommends removing a progestin IUD ~6 months before trying—what signs (bleeding patterns, ultrasound findings) indicate endometrial recovery is adequate sooner or needs longer?
The episode clarifies what can and cannot be tested: egg quantity (ovarian reserve) is approximated by AMH, while egg quality is inferred mainly from age, metabolic health, and clinical context.
Given the strong claims about cannabis harming sperm/embryos, what is the minimum abstinence window she recommends for men and women (e.g., 90 days for sperm) and what data supports that timing?
Lifestyle “non-negotiables” (sleep, stress, strength/muscle, nutrition, and toxin reduction) are positioned as major levers for egg/sperm outcomes, with specific warnings about cannabis, nicotine, and certain anti-inflammatories around ovulation.
How should couples balance “trimester zero” lifestyle optimization against the risk of waiting too long with advancing maternal age?
The discussion covers fertility preservation and assisted reproduction (egg freezing, IVF, embryo banking), addressing common myths, ethical debates, and access/insurance barriers, while highlighting patient choice and autonomy.
Chapter Breakdown
Dr. Natalie Crawford’s framework: fertility as a window into whole-body health
Huberman introduces Dr. Natalie Crawford and frames fertility as more than pregnancy—it's a marker of hormonal, metabolic, and cellular health. Crawford explains how infertility often correlates with broader health risks, not because it directly causes them, but because it can be an early warning sign of underlying inflammation or insulin resistance.
Perimenopause & menopause: redefining ovarian aging and hormone therapy timing
Crawford explains perimenopause as a long transition where cycle changes and hormone symptoms can begin years before the traditional menopause definition. She and Huberman discuss why waiting for strict cutoffs (e.g., 12 months without a period) can delay helpful care and how hormone therapy is increasingly viewed as beneficial when appropriately timed.
Extending ovarian function: inflammation, autoimmune disease, and lifestyle leverage points
The conversation shifts to what might influence ovarian lifespan beyond genetics, emphasizing inflammation and autoimmune associations with earlier ovarian insufficiency. Crawford outlines how managing inflammatory conditions and lifestyle choices could plausibly slow ovarian aging, even if definitive trials are limited.
Plastics, microplastics & endocrine disruption: what’s known and what to do
Crawford addresses concern about plastics and endocrine-disrupting chemicals, emphasizing practical risk reduction rather than perfectionism. She highlights observational links between certain exposures and worse fertility/IVF outcomes while acknowledging confounding factors and the importance of cumulative exposure.
Prior pregnancy, secondary infertility, and why earlier testing matters (including sperm)
Crawford reviews data showing prior live birth can improve fecundability (month-to-month pregnancy probability) for a time, but secondary infertility is real and emotionally complex. She strongly argues against the “fail-first” model and emphasizes early evaluation—especially semen testing—to prevent wasted time.
Pregnancy loss, termination, and conceiving again: evaluation thresholds and uterine health
Crawford discusses pregnancy loss compassionately, including her personal experience, and explains how loss can still indicate some intact fertility pathways while requiring timely evaluation. She clarifies that abortion/termination doesn’t inherently cause infertility, but any intrauterine procedure can carry scarring risk, especially with infection or heavy bleeding.
Core reproductive biology: egg number vs egg quality and how the menstrual cycle works
Crawford gives a detailed, practical explanation of ovarian physiology: women are born with their egg supply, eggs leave the ‘vault’ each month, and ovulation depends on FSH/LH and estrogen/progesterone signaling. She distinguishes egg quantity (reserve) from egg quality (genetic normalcy/competency) and explains why age is an imperfect proxy for quality.
Tooling for planning: AMH testing, what it means, and why Crawford recommends it broadly
Crawford argues most women who might want children should get an AMH (anti-Müllerian hormone) test to understand ovarian reserve, despite professional guidelines discouraging it absent infertility. She explains what AMH can and cannot tell you, why low AMH prompts investigation for root causes, and how the information changes decision-making.
Ovulation tracking as a health marker: luteal phase defects and hidden ovulatory problems
Beyond ‘regular periods,’ Crawford emphasizes tracking ovulation to detect subtle dysfunction earlier. She explains how ovulatory disorders often begin with luteal phase shortening, then progress into delayed ovulation and irregular cycles—patterns that may be missed if someone tracks only bleeding dates.
Egg freezing & IVF realities: what it does (and doesn’t) do to ovarian reserve + ethical considerations
Crawford debunks the myth that egg freezing or IVF causes earlier menopause; stimulation simply rescues eggs that would otherwise undergo natural attrition that month. She also discusses embryo vs egg freezing, attrition rates from egg to live birth, embryo disposition concerns, and the policy/insurance landscape.
Hormonal birth control and return to fertility: pill vs IUD vs Depo-Provera
Crawford explains that large studies don’t show higher long-term infertility rates after contraception, but specific methods can delay optimal conception timelines. She highlights the short half-life of the pill, the endometrial rebuilding period after progesterone IUD removal, and Depo-Provera’s uniquely prolonged ovulation suppression in some people.
Lifestyle & supplement protocol for “trimester zero”: inflammation, sleep, NSAIDs, and key supplements
Crawford lays out actionable “do, don’t do, and take” principles for improving egg/sperm quality, emphasizing sleep and overall inflammatory load. She warns that anti-inflammatory NSAIDs can prevent follicle rupture around ovulation, discusses melatonin dosing nuance, and outlines commonly used preconception supplements with better evidence.
Emerging and debated interventions: red light, GLP-1s for endometriosis, HGH, PRP, and paternal age
The episode closes with a tour of newer or less-settled tools and risk factors. Crawford discusses promising-but-inconclusive areas like red light therapy, GLP-1 agonists for inflammatory infertility/endometriosis (independent of weight loss), add-ons such as HGH in IVF, PRP approaches, and advanced paternal age risks.
Behavioral toxins & everyday endocrine disruptors: cannabis, nicotine, fragrances, receipts, and biotin lab interference
Crawford highlights high-impact exposures that are modifiable and often underestimated. She details strong associations between cannabis and impaired sperm/egg outcomes, addresses nicotine’s harms (especially via smoking data), explains how fragrance/thermal receipts can increase endocrine disruptor exposure, and warns that biotin can distort hormone lab results.
EVERY SPOKEN WORD
Install uListen for AI-powered chat & search across the full episode — Get Full Transcript
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome